Background: Cardiogenic shock remains a major cause of morbidity and mortality in patients with ST-segment elevation myocardial infarction. We aimed to assess the current trends in cardiogenic shock management, looking specifically at the incidence, use of intra-aortic balloon pump therapy and outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Conclusion:
Cardiogenic shock treated by percutaneous coronary intervention is increasing in incidence and remains a condition associated with high mortality and limited treatment options. Intra-aortic balloon pump therapy was not associated with a long-term survival benefit in this cohort and may be associated with increased early morbidity.
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Background
Mechanical reperfusion with primary percutaneous coronary intervention (PCI) and advances in pharmacological treatment have resulted in improved outcomes following acute myocardial infarction (AMI). 1 However cardiogenic shock (CS), which still complicates 7-10% of patients with AMI, continues to be associated with high mortality (40-50%). [2] [3] [4] [5] Use of the intra-aortic balloon pump (IABP) remains a popular method for mechanical assistance in patients with cardiogenic shock who do not respond adequately to standard pharmacological treatment. 6, 7 Despite the potential physiological benefits of IABP, its effectiveness as an adjunct to treat CS has been questioned with recent evidence from several meta-analyses, registries and recent randomised controlled trials (IABP-SHOCK II) suggesting no benefit of the device. [8] [9] [10] [11] [12] [13] [14] As a result both joint American (American Heart Association (AHA)/American College of Cardiology (ACC)) and European Society of Cardiology (ESC) guidelines do not recommend the routine use of IABP in this context. 6, 12, 15, 16 Additionally, there is also limited evidence assessing the effect of IABP therapy on longer-term outcomes.
The aims of this study were to describe trends in the incidence, management, utilization of IABP therapy and long-term mortality outcomes in patients with ST-elevation myocardial infarction (STEMI) complicated by CS treated by primary PCI in a large regional network of heart attack centres.
Methods
This was an observational cohort study using a merged database from the eight London Heart Attack Centres who collect data based on the British Cardiac Intervention Society (BCIS) dataset.
Study database
The UK BCIS audit collects data from all hospitals in the UK that perform PCI, recording information about every procedure performed. 17 The database is part of the suite of datasets collected under the auspices of the National Institute for Cardiovascular Outcomes Research (NICOR) and is compliant with UK data protection legislation. Data are collected prospectively at each hospital at the time of the procedure, electronically encrypted and transferred online to a central database. Each patient entry offers details of the patient journey, including the method and timing of admission, inpatient investigations, results, treatment and outcomes. Patients' survival data is obtained by linkage via the patients' National Health Service (NHS) numbers to the Office of National Statistics, which records alive/death status and the date of death for all deceased patients.
Population study and design
We examined 21,270 consecutive patients with STEMI treated with primary PCI between January 2005-July 2015 at all eight tertiary cardiac centres in London, UK. There are no other centres in London that undertake primary PCI. Anonymous datasets with linked mortality data from the Office of National Statistics were merged for analysis from the eight centres. The study cohort consisted of 1890 (8.9%) STEMI patients with cardiogenic shock.
Cardiogenic shock was defined as systolic blood pressure <90 mm Hg due to cardiac insufficiency with clinical signs of hypoperfusion (cold extremities, oliguria, altered mental state etc.), not responsive to fluid resuscitation for more than 30 min, with a cardiac index below 1.8 l/min/m 2 without support or 2.0-2.2 l/min/m 2 with support, and in the presence of a raised pulmonary capillary wedge pressure (>15 mm Hg). 18 Additionally, patients requiring inotropes or vasopressors to maintain their systolic blood pressure >90 mm Hg were included in the study population. 18 BCIS only records cardiogenic shock status at the time of PCI procedure. Data on subsequent development of cardiogenic shock post-procedure during the hospital admission is not captured by the database and therefore we included patients who underwent PCI in the setting of CS (prior to or during the procedure).
Patients were classified into IABP or no IABP groups. The IABP group included all patients in whom IABP insertion was attempted. All patients with onset of symptoms of <12 h and at least 1 mm ST-segment elevation in two or more contiguous limb leads or at least 2 mm in two or more contiguous precordial leads or left bundle branch block were considered for primary PCI. Coronary angiography was performed via the radial or femoral artery. The culprit lesion was identified and crossed with an angioplasty guidewire. Manual thrombus aspiration was performed at the discretion of the operator followed by conventional PCI to the culprit vessel.
Clinical outcomes
Patient clinical and demographic data, procedural characteristics, bleeding complications, procedural complications, all cause in-hospital mortality, non-fatal myocardial infarction (MI), re-intervention and stroke were recorded during the admission. In-hospital major adverse cardiac events (MACEs) were defined as death, myocardial reinfarction (new pathologic Q waves in the distribution of the treated coronary artery with an increase of creatine kinase-MB to ≥2 times the reference value or significant rise in troponin biomarkers), stroke and repeat target vessel revascularisation. Procedural complications recorded included myocardial infarction, emergency coronary artery bypass grafting (CABG), arterial complications, aortic/ coronary dissection, side branch occlusion and arrhythmia. Following discharge, long-term all-cause mortality was obtained by linkage to the Office of National Statistics. Successful primary PCI result was defined as final Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 and residual stenosis <20% in the infarct-related artery at the end of the procedure.
Ethics
The data was collected as part of a mandatory national cardiac audit and all patient identifiable fields were removed prior to analysis. The local ethics committee advised us that formal ethical approval was not required.
Statistical analysis
Clinical characteristics of IABP versus no IABP treated patients were compared using the Pearson Chi Square test for categorical variables and Student t test for continuous variables. Normality of distribution was assessed using the Shapiro-Wilks test. We calculated Kaplan-Meier product limits for cumulative probability of reaching an end point and used the log rank test for evidence of a statistically significant difference between the groups. Time was measured from the first admission for a procedure to outcome (all cause mortality). Cox regression analysis was used to estimate hazard ratios (HRs) for the effect of IABP therapy in age-adjusted and fully adjusted models, based on covariates (p<0.05) associated with the outcome. A number of co-variates were included in the model, including age, gender, diabetes, hypertension, hypercholesterolaemia, previous CABG, previous PCI, previous MI, multi-vessel disease, chronic renal failure, pre-procedure TIMI flow, glycoprotein (GP) IIb/IIIA use, culprit vessel and procedural success. The proportional hazards assumption was evaluated by examining log (-log) survival curves and additionally was tested with Schoenfield's residuals. The proportional hazard assumption was satisfied for all outcomes evaluated. In addition, a sensitivity analysis was performed to evaluate the effect of including or excluding ejection fraction or PCI to the multivariate model. In the case of missing data (except for left ventricular ejection fraction (LVEF)), unknown values were imputed to the most common categorical variable and to the median or subgroup-specific median of continuous variables.
A propensity score analysis was carried out using a non-parsimonious logistic regression model comparing IABP and no IABP patients. Multiple variables were included in the model, including age, gender, diabetes, hypertension, hypercholesterolaemia, previous CABG, previous PCI, previous MI, multivessel disease, chronic renal failure, pre-procedure TIMI flow, culprit vessel, procedural success and GP IIb/IIIA use. After ranking propensity score in an ascending order, a nearest neighbour 1:1 matching algorithm was used with calipers of 0.2 standard deviations of the logit of the propensity score. Each IABP and no IABP patient was used in at most one matched pair, to create a matched sample with similar distribution of baseline characteristics between observed groups. Based on the matched samples, the Cox proportional hazard model was used to determine the association of IABP on mortality over follow-up. STATA version 10 was used for all analyses.
Results
The study population consisted of 1890 patients with a mean age of 65.80 years and 25.1% were women. Of the patients, 42.3% had hypertension, 35.4% had dyslipidaemia, 37.6% were active or ex-smokers and 32.4% had diabetes. As expected, for patients with shock, the majority of PCI procedures were performed through the femoral route, being the access route of choice for each study year and accounting for 82.1% of procedures throughout the study period. 65.9% received a GP IIb/IIIa inhibitor.
Rates of cardiogenic shock increased over the study period from 7% in 2005 to 13% in 2015 (p<0.0001) with a consistently high mortality ranging from 45-70% ( Figure 1 
Patient characteristics (Table 1)
Overall, the IABP group were younger, more likely to be male and more likely to have poor left ventricular (LV) function (defined as an ejection fraction of <35%) compared to the no IABP group. In addition, there were higher rates of previous PCI in the no IABP group. However, no differences in either call or door to balloon times were seen between the two groups.
Procedural characteristics and outcomes (Table 2)
There were higher rates of femoral access in the IABP group compared to the no IABP group. Rates of multi-vessel disease were similar between the groups although higher rates of multi-vessel intervention were seen in the IABP group. There were higher rates of left main and left anterior descending intervention in the IABP group with higher rates of right coronary artery intervention in the no IABP group. Overall there were similar mean stent lengths/widths and procedural success rates in the IABP group compared to the no IABP group. 
In-hospital outcome

Long-term outcome
Patients were followed-up for a median of 4.1 years (interquartile range (IQR): 2.2-5.8 years). Kaplan-Meier analysis demonstrated that there was a statistically significant difference in mortality rates between the two groups (50.9% IABP vs 39.9% no IABP, p<0.0001) (Figure 4 ).
Predictors of all-cause mortality
Age-adjusted Cox analysis (Table 3, Figure 5 ) revealed that IABP use was a univariate predictor of all-cause mortality (HR 1.46, 95% CI 1.23-1.74). However, after multivariate adjustment ( Figure 6 ), IABP use was not associated with rates of all-cause mortality 1.04 (0.62-1.89). This was the same even if ejection fraction (available for only 40% of patients) was excluded as a covariate in the analysis (HR 1.14, 95% CI 0.63-1.52). In addition, when adding the PCI centre to the analysis, IABP was still not associated with rates of all-cause mortality (1.27, 95% CI 0.83-1.71).
Stratification of risk by propensity score
After regression adjustment incorporating the propensity score into a proportional hazard model as a covariate, IABP therapy was not associated with rates of all-cause mortality (HR: 1.26, 95% CI 0.83-1.94). The model fit to determine the propensity score had good discrimination (C statistic 0.79). Analysis of patients stratified by quintiles of propensity score showed that the frequency of IABP use increased progressively from low to high-risk patients (27.9% in Q1 vs 54.1% in Q5; p=0.008; Table 4 ). Overall five-year mortality rates also increased from Q1 to Q5. The risk ratio for five-year mortality associated with procedures using IABP compared with non-IABP procedures across all quintiles of baseline risk was 1.54 (95% CI 0.94-2.52). Among patients in all the quintiles of propensity score, five-year mortality rates were similar in IABP group and the non-IABP groups.
Propensity matching
To further account for confounding variables and bias, propensity score matching was performed to adjust for differences in demographic and procedural variables producing a total of 1360 patients (680 in the IABP group and 680 in the no IABP group). Following matching, the baseline demographics and procedural variables were well balanced in the two propensity-matched cohorts. In the propensitymatched cohorts, Cox regression analysis revealed that the 
Discussion
This study illustrates the year-on-year increase in CS treated by primary PCI in the population of a large metropolitan city. This study confirms CS is a devastating condition with mortality rates ranging from 40-70%. Consistent with recent randomised trials and meta-analyses, IABP therapy was not associated with a reduction in mortality over long-term follow-up. Although the use of IABP was restricted to the highest risk cases of shock with significant baseline differences between the two groups, no benefit was seen even after correction for these higher risk baseline variables. This study shows that there is a clear unmet need to improve outcomes in this clinical setting. In our study, the overall rate of CS complicating STEMI was 8.9%, with the proportion of STEMI patients developing CS increasing from 7.0% in 2005 to 13% in 2015. The incidence of CS in AMI has ranged from 5-10% in previously published studies 3, 19 but with conflicting reports on trends in its incidence. Large contemporary studies from both the USA (Kolte) and the UK (BCIS) demonstrate increasing rates of CS seen over recent years, 3, 18, 20 however other studies such from France 4 and Switzerland 21 have shown declining rates of CS. Important differences exist between these studies. This study and the national US/UK studies consist of PCI populations and patients presenting to catheterization laboratories in CS whereas the two European studies examine CS as a whole (with rates of PCI at 50% and 65%) and large numbers developing CS in hospital. Against this is a recent intensive care unit (ITU) study demonstrating increasing rates again. Importantly, the population in this study which is from a large metropolitan area with a diverse ethnic and social makeup, including all primary PCI patients across the London area over the timeperiod, provides a large unselected urban population for robust linkage analysis to mortality which may explain the rates of CS at the higher end of that in the published literature. It is unclear why rates of CS are increasing, however, this may be related to an improvement in the reporting of CS over the time period especially with the introduction of operator reported outcomes.
IABP is the most widely used LV support device for a variety of indications, including CS during primary PCI. IABP has been shown to lead to augmentation of coronary blood flow, unloading of the left ventricle and subsequent increase in myocardial oxygen supply by improving the peak diastolic pressure and lowering the end-systolic pressure by means of diastolic inflation and rapid systolic deflation. 22, 23 Despite these favourable haemodynamics, IABP is associated with important complications such as major bleeding, stroke, local/systemic infections and vascular complications 24 which may limit its beneficial effects. In this study IABP use was associated with significantly higher rates of both arterial complications and rates of major bleeding highlighting potential detrimental effects of IABP use, a finding consistent with a Cochrane meta-analysis. 25 In addition, another mechanism for the ineffectiveness of IABPs in CS patients may be released to the lack of haemodynamic efficacy with counterpulsation pumps when native LV function is severely impaired. During cardiogenic shock, there is irreversible damage due to diminished organ perfusion and inflammatory responses. Hence, providing mechanical haemodynamic support may not be enough to reverse the damage that has already occurred. 26 Our data supports the recent recommendations of the ACC/ AHA and ESC guidelines to downgrade the level of recommendation for the use of IABP therapy. 6, 15, 27 Data assessing the use of IABP in patients with AMI complicated by CS is conflicting. Despite promising early data, 28 the most recent and largest randomised trial assessing IABP use in CS secondary to AMI (IABP-SHOCK II study) which assigned 600 patients to either IABP or no IABP therapy demonstrated no difference in the primary endpoint of 30-day mortality (IABP group 40%, no IABP group 41%; relative risk (RR) 0.96, 95% CI 0.79-1.17). 13 The latest 12-month results strengthen these findings as the 12-month mortality did not differ between the two groups (IABP group 52%, no IABP group 51%; RR 1.01, 95% CI 0.86-1.18). Furthermore, there were no significant differences between the two groups in the frequency of stroke, re-infarction, functional class or quality of life indices. 12 The timing of IABP insertion has been a criticism of this study as the IABP was generally inserted after the primary PCI procedure was completed 29 which may be too late, although more recent data has suggested that IABP insertion before primary PCI was not associated with a more favourable outcomes compared to patients those started after primary PCI, 30 making the criticism less justified.
Our findings are consistent with other registry data 9 where, in a series of 7268 patients, IABP showed no mortality benefit after primary PCI, and a recent meta-analysis 8 which used a meta-regression analysis model to correct for differences in baseline inequalities and found that the outcome after IABP was similar to that seen in the majority of randomised control studies of IABP in primary PCI (i.e. no difference in mortality between IABP and no IABP use). 10, 11, 13, 14 Other studies have suggested a potential harmful association of IABP therapy and outcome. 18 However, it is possible that IABP use is simply a marker of worse clinical state at presentation and the perception in operators' minds that it might be of value in such patients. This was evident in our study as the use of IABP was highest in our 'high risk' CS group (55.6%) compared to the 'low risk' group (6.5%). Furthermore, the fact that unadjusted long-term mortality in the IABP group was twice as high compared to the no IABP group would also be consistent with operators' deciding to use IABP in patients who are felt to be in the highest risk groups.
In clinical practice, the utilisation rate of IABP has been described as low (15-30 %) . 31, 32 In our analysis with data from a large cohort of shock patients from London, the use of IABP was 38% with large differences in the use of IABP between the hospitals, ranging from 23-53%. One reason for the overall low utilisation rate of IABP in shock might be that interventionalists are not fully convinced about the beneficial effect of IABP on top of early revascularization therapy, as well as concerns about the potential complications of IABP. In addition, despite falling rates of IABP use (in keeping with data from a large registry of 76,474 patients), 33 rates of CS have increased over time (Figure 1) suggesting the definitive need for alternative mechanical support therapies to treat CS or more targeted approaches to target those most likely to benefit.
Newer therapies such as percutaneous ventricular assist devices (e.g. Impella or Heartmate PHP) and other therapies such as extracorporeal membrane oxygenation (ECMO) have emerged but data to date are limited. The Impella 2.5 (Abiomed, Danvers, Massachusetts, USA) has not demonstrated an effect on outcomes in both a European registry (Impella-EUROSHOCK) 34 and a small randomised controlled trial (RCT; 25 patients) where Impella was compared with IABP, despite superior haemodynamic measurements in Impella patients. 35 The device has recently been awarded US Food and Drug Administration (FDA) approval for its use in patients with CS and one RCT (IMPRESS in Severe Shock trial) has found no benefit in the reduction of 30-day mortality in patients with CS compared to IABP. 26 There is another RCT evaluating Impella CP in the setting of CS: the Danish Cardiogenic Shock Trial (Impella CP versus optimal medical therapy, NCT01633502). Another support therapy that has been developed is ECMO. Both Impella therapy and ECMO can be rapidly set up if the expertise and infrastructure is available locally. However, to date, there are no RCTs comparing ECMO to IABP or other support therapies and a recent meta-analysis of 20 studies consisting of over 1800 patients with cardiogenic shock or cardiac arrest showed high complication rates with ECMO therapy, with high rates of lower extremity ischaemia and major or significant bleeding, 36 suggesting that more study is needed. Finally, TandemHeart percutaneous ventricular assist device (pVAD) may be useful in the management of CS. In a study, 42 patients with CS were randomised to treatment with IABP or TandemHeart pVAD and it was found that TandemHeart significantly improved haemodynamic parameters, even in patients failing IABP. 37 These findings were similar to a study by Thiele et al. where a similar sized study found improvement in cardiac output and other haemodynamic indices with the pVAD compared to IABP use. 38 Our study supports the RCTs, current observational data and current level III guideline recommendations for the use of IABP therapy in patients with CS, treated with primary PCI. 16, 27, 39 In the setting of primary PCI, routine use of IABP counterpulsation should not be the default therapeutic approach. However, it is still likely to be used in bailout strategies as evidenced by rates in current practice of 25% of CS patients 40 despite RCT and guideline data until other forms of effective mechanical support are available.
Strengths and limitations of this study
The strength of this study is that it includes patients from eight different centres in a large metropolitan city with a diverse ethnic and social make-up. The study includes patients with previous CABG and other co-morbidities, and is thus representative of the broad range of patients encountered in day-to-day clinical practice. Whilst inclusion of such patients may result in some baseline differences between the groups, differences were mitigated by use of multivariate analyses. To further account for confounding variables and bias, propensity analyses were also performed, which were in agreement with findings from other cohort analyses. Mortality tracking in England is particularly robust based on official UK Office of National Statistics data and hence our mortality end-point is reliable. The multivariate analyses is also reassuring as it confirms that well-recognised predictors of mortality were associated with adverse outcomes in our data set. However, our study has limitations. First of all, our study only applies to patients with STEMI who received primary PCI. In addition, this study has all the limitations of a registry and all the potential bias and unmeasured confounding associated with non-randomised studies. Specifically, we do not have information regarding the following variables in our registry: details of blood pressure measurements, details of resuscitation before procedure; details of mechanical complications; use of ECMO; and the use of LV assist devices. In addition, we cannot exclude the possibility of under-reporting of complications although the tracking of mortality is robust.
Conclusion
CS remains a major cause of mortality after AMI with evidence to suggest an increasing incidence of this difficult to treat condition. High mortality rates remain, and in this large cohort of patients with AMI complicated by cardiogenic shock IABP therapy was not associated with a longterm survival benefit supporting the decreased utilization seen. There is, therefore, a definitive need for alternative mechanical support therapies to treat CS.
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